News | January 05, 2022
Bharat Biotech's intranasal vaccine Phase 3 trials gets approval
It has also been granted permission to conduct trials for booster dose
It has also been granted permission to conduct trials for booster dose
Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
Partnering to build biosynthesis processes and a pharmaceutical production platform
The combination enhances Comar's customer value proposition by adding complementary closure and jar products and related precision mold-making expertise
In India, healthcare has become one of the fastest-growing economic sectors which comprise hospitals, pharma companies, medical equipment and devices, medical tourism, health insurance, clinical trials etc
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
Flattish volume growth and subdued new launches were key factors for last month
SK bioscience secures long-term license to supply the Novavax vaccine for the Korean market
The single-dose vaccine has been approved in China, Mexico, Ecuador, Chile, Argentina, Hungary, Kirghizstan, Pakistan, Indonesia and Malaysia
Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant
Subscribe To Our Newsletter & Stay Updated
